Kalshi Seeks $40B Valuation Amid Crypto Market Shakeup
Kalshi is courting a lofty valuation after a recent funding round, signaling confidence in prediction markets amid a ...
Using Loyalty Programs With Credit Card Points
Discover how using loyalty programs with credit card points can boost your rewards. Make your points go further.
20,311 articlesForget Mastercard: One Dominant Payment Tollbooth to Buy
Investors are increasingly circling a single dominant payments network that could redefine how money moves worldwide,...
Ally Financial and Chime Financial: Which Stock Is a Buy
Two very different players dominate the modern financial scene: Ally Financial builds on auto lending with a growing ...
U.S. Debt Looming Crisis Tests Global Markets Today
Debt trends are shifting from policy tool to market risk. This report explains how the U.S. rose to financial promine...
Reasons Higher Prices Good for Banks: 2 Upsides and 1 Risk
Oil price moves can lift bank profits in certain scenarios. This article breaks down two upside reasons higher prices...
Angel Oak’s Hutchens Growth Path in Non-QM Loans Gains Steam
As rates cool, Angel Oak’s Hutchens charts a growth path for non-QM lending with a sharper focus on product expansion...
Fund Just Opened Million: Key Takeaways on Trustmark
A fund just opened million in Trustmark shares signals conviction, but it isn’t a guaranteed win. This guide explains...
AI Frenzy Could Trigger Stock Slump, BIS Warns of Risk
The BIS warns that AI-driven hype could trigger a stock-market pullback and spill into credit markets, threatening gl...
The Ultimate “stress Test” Housing Market: 2026 Edition
What counts as the ultimate “stress test” for housing in 2026? This article breaks down signals, scenarios, and pract...
Stocks Market Drops Again: 5 Buys for a Downturn Today
When the market falters, smart investors pivot to high-quality names. This guide outlines five durable stocks to buy ...
Meet Billionaires Bankrolling March Madness Sweet 16 Powerhouses
Billionaire donors are steering college hoops beyond winnings, fueling facilities, NIL deals, and recruiting as the S...
CRISPR Therapeutics $2.4 Billion Cash: Why the Stock Slump Persists
CRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
Popular Topics
Fable
Smart Money Moves For Everyday Life
Investment Strategies In Energy Sector
Best Index Funds For Retirement
Investment Strategies
Untitled D6eff7ea
Crypto For Beginners
Best Dividend Etfs
Index
Innovative Skincare Clinical
Dutch Salary
Blue Owl
Budget
Ai Healthcare News
Penalty Vs No Penalty Depending On Lock Status